| 25.06 08:12 | dpa-AFX: *ASTRAZENECA : IMFINZI FAILS TO MEET PRIMARY ENDPOINT IN EARLY-STAGE NSCLC TRIAL |
| 25.06 08:03 | dpa-AFX: *ASTRAZENECA :IMFINZI SHOWS SIGNIFICANT SURVIVAL BENEFITS IN BLADDER CANCER TRIAL |
| 24.06 09:09 | dpa-AFX: ANALYSE-FLASH: Barclays belässt Astrazeneca auf 'Overweight' - Ziel 13500 Pence |
| 24.06 09:09 | dpa-AFX: Barclays belässt Astrazeneca auf 'Overweight' - Ziel 13500 Pence |
| 18.06 12:33 | dpa-AFX: ANALYSE-FLASH: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15200 Pence |
| 18.06 12:33 | dpa-AFX: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15200 Pence |
| 18.06 08:31 | dpa-AFX: AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer |
| 18.06 08:06 | dpa-AFX: *ASTRAZENECA : PHASE III TRIAL OF TRUQAP PLUS CHEMOTHERAPY IN ADVANCED BREAST CANCER FAILS TO MEET MAIN GOAL |
| 18.06 08:06 | dpa-AFX: *ASTRAZENECA SAYS CAPITELLO-290 PHASE III TRIAL FOR TRUQAP + CHEMOTHERAPY FAILS TO MEET DUAL PRIMARY ENDPOINTS OF IMPROVEMENT IN OVERALL SURVIVAL |
| 17.06 08:25 | dpa-AFX: AstraZeneca's Imfinzi Plus Chemotherapy Approved In The US For Endometrial Cancer |
| 17.06 08:02 | dpa-AFX: *ASTRAZENECA : FDA OKS IMFINZI PLUS CHEMOTHERAPY FOR MISMATCH REPAIR DEFICIENT ADVANCED OR RECURRENT ENDOMETRIAL CANCER |
| 17.06 08:02 | dpa-AFX: *ASTRAZENECA SAYS IMFINZI PLUS CHEMOTHERAPY APPROVED IN THE US FOR ENDOMETRIAL CANCER |
| 16.06 18:04 | dpa-AFX: AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial |
| 13.06 03:13 | dpa-AFX: FDA Approves AstraZeneca's Farxiga For Pediatric Use In Type-2 Diabetes |
| 10.06 13:30 | dpa-AFX: AstraZeneca's Tagrisso Gets Priority Review In US In Stage III EGFR-mutated Lung Cancer |
| 10.06 13:05 | dpa-AFX: *ASTRAZENECA SAYS TAGRISSO GRANTED PRIORITY REVIEW IN US FOR PATIENTS WITH STAGE III EGFR-MUTATED LUNG CANCER |
| 10.06 07:34 | dpa-AFX: ANALYSE-FLASH: Berenberg hebt Ziel für Astrazeneca auf 15000 Pence - 'Buy' |
| 10.06 07:34 | dpa-AFX: Berenberg hebt Ziel für Astrazeneca auf 15000 Pence - 'Buy' |
| 10.06 07:00 | dpa-AFX: *BERENBERG RAISES ASTRAZENECA PRICE TARGET TO 15000 (13000) PENCE - 'BUY' |
| 10.06 07:00 | dpa-AFX: *BERENBERG HEBT ZIEL FÜR ASTRAZENECA AUF 15000 (13000) PENCE - 'BUY' |
|
|
